#United States #Emeryville #Dynavax #HEPLISAV-B #vaccines

Dynavax Technologies Reports Financial Results and 2025 Plans

Dynavax Technologies Corporation (Nasdaq: DVAX) has announced its financial results for the fourth quarter and full year ending December 31, 2024. The biopharmaceutical company, known for developing and commercializing innovative vaccines, reported record earnings from its flagship product, HEPLISAV-B, and provided a positive financial outlook for 2025.

Strong Performance in 2024

For the full year of 2024, Dynavax achieved net product revenues of $268 million, reflecting a remarkable 26% increase compared to 2023. This robust performance was primarily driven by the HEPLISAV-B vaccine, which garnered $71 million in revenue for the fourth quarter alone, up 39% year-over-year.

Ryan Spencer, CEO of Dynavax, expressed satisfaction with the company's operational success, highlighting the strategic initiatives that contributed to these positive results. "In 2024, we successfully executed on our strategic growth initiatives, achieving record HEPLISAV-B product revenue, advancing our pipeline programs, and maintaining a disciplined approach to capital allocation," he said.

Forecast for 2025

Looking ahead, Dynavax anticipates net product revenue for HEPLISAV-B to be between $305 and $325 million in 2025. The company also aims to enhance its operational capabilities, with an expectation to reach vital milestones in its pipeline programs, such as top-line results from its shingles vaccine Phase 1/2 study and the initiation of a Phase 2 trial for a plague vaccine later this year.

Additionally, Dynavax announced plans to complete a $200 million share repurchase program in 2025, underlining the firm’s commitment to returning value to shareholders.

Commercialization of HEPLISAV-B

The HEPLISAV-B vaccine stands out in the market as it is the only hepatitis B vaccine approved for adults that only requires two doses within one month for complete series vaccination. As of the end of 2024, its total estimated market share in the U.S. rose to 44%, positioning it favorably as a leading option in the expanding hepatitis B vaccine market, projected to reach over $900 million in annual sales by 2030.

Dynavax has marked a significant penetration strategy into the market, expecting to capture at least 60% of the total market share, thanks to the unvaccinated adult populations and revaccination trends among healthcare providers.

Advancing Clinical Programs

Dynavax is not resting on its laurels as it continues to advance its clinical pipeline, leveraging its proprietary CpG 1018® adjuvant to enhance immune responses. Key programs include:

• - Shingles Vaccine Program: The trial, known as Z-1018, aims to prevent shingles in older adults. It successfully completed enrollment with results expected in Q3 2025.
• - Plague Vaccine Program: Funded entirely by the U.S. Department of Defense (DoD), this candidate is currently in a Phase 2 trial with expectations to begin further studies in late 2025.

Furthermore, Dynavax plans to develop a unique HEPLISAV-B dosage regimen for adults undergoing hemodialysis, marking another step in expanding its product lineup.

Financial Highlights of the Quarter

For Q4 2024, Dynavax showed total revenues of $72 million, a 30% increase from Q4 2023. Adjusted EBITDA, a non-GAAP measure reflecting earnings before interest, taxes, depreciation, and amortization, saw a staggering 225% increase, highlighting the company’s operational efficiency and growth trajectory.

With cash reserves totaling $713 million, Dynavax maintains a strong financial position as it navigates the upcoming year and pursues broader market opportunities.

Conclusion

Dynavax Technologies is poised for a promising 2025, with strategic growth initiatives in place aimed at establishing HEPLISAV-B as a leading vaccine in the market while advancing its diversified clinical pipeline. With a commitment to innovation and shareholder value, the company looks set to make significant strides in combating infectious diseases, reinforcing its position in the biopharmaceutical landscape.